X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Autogene cevumeran (RO7198457) is a messenger RNA (mRNA)-based personalized cancer vaccine, which is being evaluated in combination with atezolizumab for the treatment of resected pancreatic ductal adenocarcinoma.
Lead Product(s): Autogene Cevumeran,Atezolizumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: RO7198457
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
Tecentriq (atezolizumab) is a USFDA approved programmed death-ligand 1 (PD-L1) blocking antibody. It is being evaluated for the treatment of alveolar soft part sarcoma, an ultra-rare disease.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
Through the acquisition, Merck leverages Harpoon lead candidate HPN328 (MK-6070), which is being evaluated in Phase I/II clinical trial studies in combination with Atezolizumab for the treatment of Small-cell Lung Cancer.
Lead Product(s): MK-6070,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 11, 2024
Details:
Under the collaboration, Roche will conduct clinical trial studies to evaluate the safety, efficacy of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab for the treatment of locally advanced hepatocellular carcinoma.
Lead Product(s): IO-108,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2024
Details:
Reolysin (pelareorep) is an oncolytic reovirus, which can induce a T cells-inflamed phenotype in PDAC. It is being evaluated in combination with atezolizumab in patients with second-line or later unresectable squamous cell carcinoma of the anal canal.
Lead Product(s): Pelareorep,Atezolizumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Tecentriq (atezolizumab) is a PDL-1 inhibitor monoclonal antibody, It is approved by EMA for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Halozyme Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Tecentriq® SC (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for urothelial carcinoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma & melanoma.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq SC
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
AFM24 is a tetravalent, bispecific innate cell engager that binds to CD16A on innate immune cells and EGFR. It is under phase 1/2 clinical development in combination with atezolizumab for the treatment of EGFR-Wildtype Non-Small Cell Lung Cancer.
Lead Product(s): AFM24,Atezolizumab
Therapeutic Area: Oncology Product Name: AFM24
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
The acquisition will expand Merck's oncology portfolio by including HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $680.0 million Upfront Cash: $680.0 million
Deal Type: Acquisition January 08, 2024
Details:
AFM24 is a tetravalent, bispecific innate cell engager that activates innate immune system by binding to CD16A on innate immune cells and EGFR. AFM24 in combination with atezolizumab is being evaluated in heavily pre-treated EGFR-wildtype non-small cell lung cancer patients.
Lead Product(s): AFM24,Atezolizumab
Therapeutic Area: Oncology Product Name: AFM24
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care Tecentriq (atezolizumab) and Avastin (bevacizumab) in first-line treatment of unresectable/advanced hepatocellular carcinoma.
Lead Product(s): NKT2152,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2023
Details:
XTX101 is an antibody infusion therapy inhibiting CTLA-4, is being investigated for the treatment of microsatellite stable colorectal cancer in combination with Atezolizumab.
Lead Product(s): XTX101,Atezolizumab
Therapeutic Area: Oncology Product Name: XTX101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
Tecentriq (atezolizumab) is a PDL-1 inhibitor monoclonal antibody, which is currently being evaluated in phase 3 clinical trials for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Reolysin (pelareorep), an intravenously delivered immunotherapeutic agent, which is investigated in combination with atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal.
Lead Product(s): Pelareorep,Atezolizumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
Sonnet anticipates using the net proceeds from the offering for research and development, including SON-1010 (IL12-FHAB), a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform.
Lead Product(s): IL12-FHAB,Atezolizumab
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chardan
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 25, 2023
Details:
Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) and platinum-based chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of progression-free survival (PFS).
Lead Product(s): Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
The Company intends to use the proceeds to fund its clinical development programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328, a TriTAC that binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Soleus Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 23, 2023
Details:
BNT122 is a mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran, which is investigated for the treatment of resected pancreatic ductal adenocarcinoma.
Lead Product(s): Autogene Cevumeran,Atezolizumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: BNT122
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
The expanded collaboration aims to study drug synergies of LIXTE’s lead clinical compound, LB-100, an inhibitor of the PP2A phosphatase, with immunotherapy in various cancers.
Lead Product(s): LB-100,Atezolizumab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Netherlands Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 16, 2023
Details:
TPST-1120 is an oral, small molecule, selective PPAR alpha antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for unresectable or metastatic hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq for the treatment of small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
HPN328, is a DLL3 targeting TriTAC®, which is investigated in combination with atezolizumab for the treatment of patients with small cell lung cancer.
Lead Product(s): HPN328,Atezolizumab
Therapeutic Area: Oncology Product Name: HPN328
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388 (casdozokitug), a novel IL-27-targeted antibody being evaluated in Phase 2 in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced solid tumors.
Lead Product(s): Casdozokitug,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $66.9 million Upfront Cash: $26.9 million
Deal Type: Acquisition September 08, 2023
Details:
Tecentriq (atezolizumab) is a monoclonal antibody, binds with PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, drug may enable the activation of T-cells.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Halozyme Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
MTIG7192A (tiragolumab) is a novel immune checkpoint inhibitor with an intact Fc region, which is investigated in combination with Tecentriq® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high non-small cell lung cancer.
Lead Product(s): Tiragolumab,Atezolizumab
Therapeutic Area: Oncology Product Name: MTIG7192A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
SON-1010 is a proprietary version of recombinant human Interleukin 12, configured using the FHAB technology that targets tumor and lymphatictissue, which is being investigated with a fixed dose of atezolizumab for the treatment of platinum-resistant ovarian cancer.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.
Lead Product(s): HTL0039732,Atezolizumab
Therapeutic Area: Oncology Product Name: HTL0039732
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq in extensive-stage small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
ARB202 (atezolizumab) is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: ARB202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tagrisso in advanced non-small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX Nanoparticle Delivery System and Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
SON-1010 is a proprietary version of recombinant human Interleukin 12 (IL-12), configured using the FHAB technology that targets tumor and lymphatictissue, which is investigated for the treatment of patients with advanced solid tumors.
Lead Product(s): IL12-FHAB,Atezolizumab
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388, a novel IL-27-targeted antibody being evaluated in Phase 2 trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced solid tumors.
Lead Product(s): SRF388,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $65.0 million Upfront Cash: $25.0 million
Deal Type: Acquisition June 16, 2023
Details:
The collaboration aims to cover evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer. Nykode will sponsor the trial, and Roche will provide atezolizumab.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 01, 2023
Details:
DSP107, a dual, first-in-class CD47 and 4-1BB targeting fusion protein that activates innate and adaptive immunity, is being developed in combination with atezolizumab, an anti-PD-L1 in patients with advanced solid tumors.
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
AB011 is a humanized CLDN18.2 monoclonal antibody (mAb) product that has received an investigational new drug (IND) approval from the National Medical Products Administration (NMPA) for the treatment of CLDN18.2 positive solid tumors.
Lead Product(s): AB011,Atezolizumab,Capecitabine
Therapeutic Area: Oncology Product Name: AB011
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
TPST-1120 is an oral, small molecule, selective PPAR⍺ antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adagene Suzhou Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
TPST-1120 target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a monotherapy or in combination with other approved agents.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate targeting antigens to antigen presenting cells. It is in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Tecentriq (atezolizumab) is a monoclonal antibody, binds with PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, drug may enable the activation of T-cells.
Lead Product(s): Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2023
Details:
LIXTE’s first-in-class protein phosphatase 2A (PP2A) inhibitor LB-100 with a standard regimen for previously untreated, extensive stage disease small cell lung cancer (ED-SCLC).
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Under the agreement, Omega will evaluate OTX-2002 in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial.
Lead Product(s): OTX-2002,Atezolizumab
Therapeutic Area: Oncology Product Name: OTX-2002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
Cabometyx (cabozantinib) is a multiple receptor tyrosine kinases inhibitor. These receptors are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, maintenance of the tumor microenvironment, etc.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
LB-100, an inhibitor of PP2A, significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It has shown significant tumor shrinkage and the arrest of tumor progression in patients with advancing cancers.
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Based on the positive interim data and in line with our potential registrational trial strategy, we look forward to starting the VB-C-04 trial in the U.S. The trial is aimed at providing a fast path to making VB10.16 available to patients.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GOG Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2023
Details:
Under the agreement, Roche will be responsible for operation and conduct of the trial while both companies co-share the costs of AB011 treatment arms in study. The co-funded study of AB011 in combination with atezolizumab will be conducted as part of Roche's Morpheus Platform.
Lead Product(s): Humanized Claudin18.2 Monoclonal Antibody,Atezolizumab
Therapeutic Area: Oncology Product Name: AB011
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 31, 2023
Details:
NP137 is a humanized monoclonal antibody of isotype IgG1 directed against netrin-1. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from apoptosis.
Lead Product(s): NP137,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: NP137
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
Tecentriq (atezolizumab) is a monoclonal antibody, binds with PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, drug may enable the activation of T-cells.
Lead Product(s): Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Tecentriq (atezolizumab) binds to PD-L1 and blocks it from binding to another checkpoint protein, PD-1. This helps T cells regain their ability to kill tumor cells.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
